Protagonist Therapeutics, INC 8-K filings

Protagonist Therapeutics announced robust second quarter 2026 financial results, highlighting the successful commercial launch of ICOTYDE, priority review for rusfertide, and significant progress across its internal R&D pipeline.

Protagonist Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved the adoption of the 2026 Equity Incentive Plan, replacing the 2016 plan.

Protagonist Therapeutics announced strong Q1 2026 results, highlighted by the FDA approval of ICOTYDE, a $50 million milestone payment, and significant advancements in its rusfertide and wholly-owned pipeline programs.

Protagonist Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting significant pipeline advancements including two NDA submissions and an extended cash runway.

Protagonist Therapeutics, Inc. provides an updated corporate presentation detailing progress on its lead drug candidates, Icotrokinra and Rusfertide, including recent NDA submissions and a robust R&D pipeline.

Protagonist Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its icotrokinra and rusfertide programs, alongside pipeline expansion.

Protagonist Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in its clinical pipeline with NDA filings for icotrokinra and rusfertide on track, alongside a strong cash position.

Protagonist Therapeutics, Inc. announced the successful approval of all three proposals at its 2025 Annual Meeting of Stockholders, including the re-election of two Class III directors, the advisory approval of executive compensation, and the ratification of its independent auditor.

Protagonist Therapeutics announces positive top-line results from the rusfertide Phase 3 VERIFY trial and reports a strong cash position of $697.9 million as of March 31, 2025.

Protagonist Therapeutics and Takeda Pharmaceuticals agree to transition leadership of the New Drug Application (NDA) preparation for rusfertide in polycythemia vera to Takeda.

Protagonist Therapeutics reports positive Phase 3 results for Icotrokinra in psoriasis and Phase 2b results in ulcerative colitis, demonstrating its potential as a novel oral treatment.

Protagonist Therapeutics announces positive clinical study results for icotrokinra in both plaque psoriasis and ulcerative colitis, suggesting a potential shift in treatment paradigms.

Protagonist Therapeutics and Takeda report positive topline results from the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera, meeting the primary endpoint and all key secondary endpoints.

Protagonist Therapeutics announces positive financial results for Q4 and full-year 2024, highlighted by a $165.0 million milestone payment and advancements in its clinical programs.

Protagonist Therapeutics has announced that Suneel Gupta, Ph.D., has transitioned from Chief Development Officer to Executive Vice President, Clinical Development, effective January 1, 2025.

Protagonist Therapeutics has earned a $165 million milestone payment from Johnson & Johnson after positive Phase 3 trial results for their psoriasis drug, icotrokinra.

Protagonist Therapeutics announced its third quarter 2024 financial results, highlighting a strong cash position and upcoming clinical trial milestones.

Protagonist Therapeutics announces the resignation of a board member and appointment of a new member to the Audit Committee.

Protagonist Therapeutics announced its second quarter 2024 financial results, highlighted by a significant increase in cash reserves and progress in multiple clinical trials.

Protagonist Therapeutics' stockholders approved an increase in authorized common stock shares from 90 million to 180 million at the 2024 Annual Meeting.

Protagonist Therapeutics announced a profitable first quarter of 2024, driven by a significant collaboration agreement with Takeda, and provided updates on their clinical programs.

Protagonist Therapeutics announced a significant collaboration with Takeda Pharmaceuticals, a $300 million upfront payment, and positive clinical trial updates for its drug candidates.

Protagonist Therapeutics has entered into a collaboration agreement with Takeda Pharmaceuticals for the development and commercialization of rusfertide, including an upfront payment of $300 million to Protagonist.

Protagonist Therapeutics highlighted advancements in their pipeline, including Rusfertide for Polycythemia Vera and JNJ-2113 for psoriasis, at the J.P. Morgan Healthcare Conference.